Fresh analysis indicates that people who discontinue popular slimming jabs like Wegovy and Mounjaro tend to recover lost weight much more quickly than those who end traditional diet and exercise regimens.
Research printed in a prominent health publication shows that while overweight people often shed substantial amounts of their total mass while undergoing treatment, the weight returns at an average rate of 0.8 kg per month after stopping.
"People buying such medications must be aware of the potential of fast rebound weight gain when the medication ends," cautioned expert Dr. Susan Jebb.
Such speed of regain implies a reversion to starting mass within about a year and a half.
Weighing Approaches
The study, which looked at dozens of trials involving thousands of participants, contrasted the outcomes of these new drugs with conventional dieting.
The team point out that individuals who lose weight through dieting typically have a more gradual weight regain—approximately 0.1 kg a month—after stopping.
Explaining the Quick Regain
Nutrition scientists believe the mechanism of the injections accounts for the accelerated regain.
The injections copy a body's own chemical called GLP-1, which helps regulate appetite.
"Long-term administration of the hormone levels several times higher than normal may cause the body to generate a reduced amount of its own natural GLP-1, and may also reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this hormone supplement results in hunger is unsuppressed, making overeating far more likely."
A Lifelong Disease?
Health authorities advise the injections for individuals with obesity-related health risks, accompanied by recommended lifestyle changes.
Many experts say that, due to the high risk of weight regain, the therapy is often life-long.
This perspective is supported by drug manufacturers, who state that the findings "highlight the chronic nature of obesity," similar to managing diseases like high blood pressure.
User Testimonies
People who have come off the medication explain a intense return of cravings.
"I experienced a switch that goes on and I was suddenly ravenous," described an individual.
This difficulty is compounded if patients have not established lasting lifestyle or habit changes during therapy.
Widespread Use
Figures suggest that a significant number of people in the UK have tried these injections in the past year, with desire being substantial.
- Use is higher among women than males.
- The middle-aged age group shows the greatest usage rates.
- Many obtain the drugs through private prescriptions rather than the NHS.
In conclusion, clinicians stress that while GLP-1 drugs are powerful agents for weight loss, they are not a magic solution and lasting health benefits hinges on combined lifestyle changes.
